Journal of Substance Abuse Treatment
Volume 39, Issue 3 , Pages 218-226 , October 2010

Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence

  • Maarten W.J. Koeter, Ph.D.

      Affiliations

    • Department of Psychiatry, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    • Amsterdam Institute for Addiction Research, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Academic Medical center University of Amsterdam, Department of Psychiatry PA1-181, Meibergdreef 5, 1105 AZ, Amsterdam, and The Netherlands Tel.: +31 0 208913632.
    • ,
  • Wim van den Brink, M.D., Ph.D.

      Affiliations

    • Department of Psychiatry, Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
    • Amsterdam Institute for Addiction Research, Amsterdam, The Netherlands
    • ,
  • Philippe Lehert, Ph.D.

      Affiliations

    • Faculty of Medicine, Department of Psychiatry, University of Melbourne, Australia
    • Statistics Department, Faculty of Economics, FUCAM, Louvain Academy, Belgium

Received 15 September 2009 ,Revised 18 May 2010 ,Accepted 4 June 2010.

References 

  1. Anton RF, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: A randomized controlled trial. JAMA. 2006;295:2003–2017
  2. Baros AM, Latham PK, Moak DH, et al. What role does measuring medication compliance play in evaluating the efficacy of naltrexone?. Alcoholism, Clinical and Experimental Research. 2007;31:596–603
  3. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcoholism, Clinical and Experimental Research. 1998;22:573–579
  4. Borg, S., unpublished data 1994.
  5. Bouza C, Angeles M, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction. 2004;99:811–828
  6. Chalmers TC, Smith H, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Controlled Clinical Trials. 1981;2:31–49
  7. Chick J, Howlett H, Morgan MY, et al. United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35:176–187
  8. Cramer JC. Effect of partial compliance on cardiovascular medication effectiveness. Heart. 2002;88:203–206
  9. DerSimonian R, Laird N. Meta analysis in clinical trials. Controlled Clinical Trials. 1986;7:177–188
  10. Duncan AJ. In: Quality control and industrial statistics. 5th ed.. Homewood, IL: Irwin; 1986;p. 229–241
  11. Edwards D. On model prespecification in confirmatory randomized studies. Statistics in Medicine. 1999;18:771–785
  12. Evangelista LS. Compliance: A concept analysis. Nursing forum. 1999;34:5–11
  13. Feinn R, Tennen H, Cramer J, et al. Measurement and prediction of medication compliance in problem drinkers. Alcoholism, Clinical and Experimental Research. 2003;27:1286–1292
  14. Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in The Netherlands, Belgium and Luxembourg. European Addiction Research. 1997;3:129–137
  15. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: A double-blind placebo-controlled study in Spain. Alcohol Alohol. 2001;36:413–418
  16. Higgins JT, Whitehead A, Turner R, et al. Meta analysis of continuous outcome data from individual patients. Statistics in Medicine. 2001;20:2219–2241
  17. Kranzler HR. Acamprosate efficacy in alcohol-dependent patients: Summary of results from three pivotal trials. American Journal on Addictions. 2008;17:70–76
  18. Kyngas H, Duffy ME, Kroll T. Conceptual analysis of compliance. Journal of Clinical Nursing. 2000;9:5–12
  19. Ladewig D, Knecht T, Leher P, et al. Acamprosate—A stabilizing factor in long-term withdrawal of alcoholic patients. Therapeutische Umschau. Revue therapeutique. 1993;50:182–188
  20. MacKinnon DP. Introduction to statistical mediation analysis. Mahwah, NJ: Erlbaum; 2008;
  21. MacKinnon DP, Lockwood CM, Williams J. Confidence limits for the indirect effect: Distribution of the product and resampling methods. Multivariate Behavioral Research. 2004;39:99–128
  22. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcoholism, Clinical and Experimental Research. 2004;28:51–63
  23. McDonough KP. Alcohol dependence and pharmacologic treatment. Introduction. American Journal Of Health-System Pharmacy. 2007;64(Suppl3):53–54
  24. McLellan AT, Lewis DC, O'Brein CP, et al. Drug dependence, a chronic medical illness. Implications for treatment, insurance, and outcome evaluation. JAMA. 2000;284:1689–1695
  25. Miller WR, Wilbourne PL. Mesa Grande: A methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction. 2002;97:265–277
  26. Pelc I, Le Bon O, Verbanck P, et al. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients; A placebo controlled double-blind multi-centre study. In:  Naranjo C,  Sellers E editor. Novel pharmacological interventions for alcoholism. New York: Springer Verlag; 1992;p. 348–352
  27. Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. The British Journal of Psychiatry. 1997;171:73–77
  28. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92:1537–1546
  29. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behavior Research Methods. 2008;40:879–891
  30. Rousseaux JP, Hers D, Ferauge M. Does acamprosate influence alcohol consumption of weaned alcoholics?. Journal de pharmacie de Belgique. 1996;51:65–68
  31. Simmonds MC, Higgins JP, Steward LA, et al. Meta analysis of individual patient data for randomized trials: A review of methods used in practice. Clinical Trials. 2005;2005(2):209–217
  32. Smith TD, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Statistics in Medicine. 2005;24:1307–1319
  33. Spanagel R, Kiefer F. Drugs for relapse prevention of alcoholism: Ten years of progress. Trends Pharmacol Sci. 2008;29:109–115
  34. Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: A placebo-controlled study. Alcohol Alcohol. 2000;35:202–209
  35. Volpicelli JR, Rhines KC, Volpicelli LA, et al. Naltrexone and alcohol dependence. Role of subject compliance. Archives of General Psychiatry. 1997;54:737–742
  36. Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opiod dependence. Addiction. 2004;99:1382–1392
  37. Wilde MI, Wagstaff AJ. Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997;53:1038–1053
  38. Yuen KH, Peh KK, et al. Comparative bioavailability study of a generic naltrexone tablet preparation. Drug Development and Industrial Pharmacy. 1999;25:353–356

 The study was made possible by an unrestricted grant from Merck. Merck also made the data available for this secondary analysis of previously conducted studies.

PII: S0740-5472(10)00129-7

doi: 10.1016/j.jsat.2010.06.002

Journal of Substance Abuse Treatment
Volume 39, Issue 3 , Pages 218-226 , October 2010

Article Tools

* Image Usage & Resolution